TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does TaiMed Biologics (4147) operate in?
TaiMed Biologics belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TaiMed Biologics (4147) current stock price?
As of the latest data, TaiMed Biologics stock price is NT$64.20, with a previous close of NT$64.20.
What is TaiMed Biologics (4147) current market capitalization?
TaiMed Biologics market cap is approximately 17.38 billion.
What is TaiMed Biologics (4147) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.46.
Does TaiMed Biologics (4147) pay dividends?
No. TaiMed Biologics does not pay a dividend.
How did TaiMed Biologics (4147) perform in its most recent earnings report?
In the last report (March 31, 2026), TaiMed Biologics posted an EPS surprise of 100% and a revenue surprise of 14.54%.
What is TaiMed Biologics (4147) beta (volatility) score?
TaiMed Biologics has a beta of -0.170, indicating lower volatility than the overall market.
